Apotex Receives First U.S. FDA Tentative Approval for Generic Ozempic

Apotex partners with Orbicular to develop affordable version of semaglutide injection.

Apr. 13, 2026 at 1:33am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray photograph revealing the intricate internal structure of a syringe filled with a glowing, ghostly liquid, suspended against a dark background and emphasizing the delicate complexity of the medical device.An X-ray view of the complex inner workings of a syringe filled with a diabetes medication, highlighting the technical sophistication required to develop a generic version.Weston Today

Apotex Corp. has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States. This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustainable healthcare system.

Why it matters

The approval of Apotex's generic version of Ozempic (semaglutide injection) will help increase competition and drive down costs for this important diabetes medication, improving affordability and access for patients. As a complex biologic drug, the development of a generic equivalent required significant scientific and regulatory expertise.

The details

Apotex developed the generic semaglutide injection through a strategic partnership with Orbicular Pharmaceutical Technologies, leveraging sophisticated development capabilities including advanced analytical characterization and deep process understanding. The FDA Tentative Approval underscores the strength of Apotex's global development model and its ability to deliver complex generics that meet rigorous regulatory requirements.

  • Apotex received the FDA Tentative Approval on April 10, 2026.

The players

Apotex Corp.

An affiliate of Apotex Inc., the largest Canadian-based pharmaceutical company that improves access to innovative medicines and health products globally.

Orbicular Pharmaceutical Technologies

A strategic partner of Apotex that provided development and execution expertise to secure the FDA Tentative Approval for the generic semaglutide injection.

Barry Fishman

Chief Corporate Development Officer at Apotex.

Dr. M.S. Mohan

Managing Director of Orbicular Pharmaceutical Technologies.

Got photos? Submit your photos here. ›

What they’re saying

“This is a clear demonstration of what true partnership can achieve. As a Force for Health, this milestone reflects Apotex's leadership in bringing together complementary strengths, a shared purpose, and an unwavering commitment to execution excellence.”

— Barry Fishman, Chief Corporate Development Officer, Apotex

“Achieving technical equivalence for complex peptide products requires deep scientific rigor, advanced analytical precision, and a highly disciplined development approach. We are proud to have supported Apotex in this important program. Their regulatory leadership coupled with Orbicular's development and execution excellence were central to securing FDA Tentative Approval.”

— Dr. M.S. Mohan, Managing Director, Orbicular Pharmaceutical Technologies

What’s next

Upon becoming eligible for final approval, Apotex's Semaglutide Injection is expected to help broaden patient access to an important therapy area where affordability and availability remain critical.

The takeaway

The approval of Apotex's generic version of Ozempic demonstrates the company's expertise in developing complex biologic medications and its commitment to improving patient access to affordable, high-quality treatments. This partnership between Apotex and Orbicular highlights the value of collaboration in advancing innovative solutions to healthcare challenges.